Denifanstat sustained acne improvement through 52 weeks in a Phase 3 open-label extension, according to new data reported by HCPLive — the longest durability readout to date for the investigational oral fatty acid synthase inhibitor in acne vulgaris.

The extension results show that improvements achieved during the pivotal Phase 3 treatment period held steady across a full year of continued dosing. For a systemic agent targeting moderate-to-severe acne, sustained efficacy at the one-year mark addresses one of the key questions dermatologists ask of any new oral therapy: does the benefit endure beyond the primary endpoint window?

What does the 52-week extension show?

The data come from the extension phase of the Phase 3 program, in which patients who completed the pivotal trial continued on denifanstat. The headline finding is durability: acne improvement measured during the core study was maintained through week 52, with no signal in the reported analysis that efficacy waned over the additional months of treatment.

Sustained response matters clinically because acne is a chronic disease. Topical retinoids and benzoyl peroxide often lose adherence over months, and oral alternatives — chiefly spironolactone and, in restricted settings, isotretinoin or antibiotics — each carry tolerability or stewardship constraints that limit long-term use.

Why the mechanism matters

Denifanstat inhibits fatty acid synthase (FASN), an enzyme central to lipogenesis in the sebaceous gland. By suppressing sebum production at its metabolic source rather than acting on androgen pathways or colonizing bacteria, the drug represents a mechanistically distinct oral option for acne.

Sebum reduction is the therapeutic anchor: excess sebum production drives comedogenesis and Cutibacterium acnes proliferation, and FASN inhibition targets that upstream step. A year of sustained efficacy on this mechanism would support the case that sebum-directed oral therapy can hold its effect without the monitoring burden associated with isotretinoin.

How the data fit the regulatory path

The extension readout builds on the pivotal Phase 3 results and extends the efficacy record from the primary endpoint horizon to a full 52 weeks. Open-label extension designs have inherent limitations — no concurrent control arm, and enrichment for patients who tolerated and responded to the drug — so the durability signal should be read as supportive rather than confirmatory.

Still, for a pipeline in which the oral acne field has seen few new entrants, a clean 52-week maintenance profile strengthens the program's regulatory and clinical narrative. Questions that remain for full labeling and practice adoption include the magnitude of effect on inflammatory and non-inflammatory lesion counts at week 52, the tolerability profile over the longer exposure period, and how dermatologists would position the agent against established systemics.

Derm Field will track the full dataset as detailed week-52 results — including lesion-count endpoints and safety tables — are presented or published.

What comes next

Longer-term open-label data of this kind typically feed directly into regulatory submissions and, if approved, into label language on duration of use. If the full 52-week analysis confirms the sustained improvement reported in the extension, denifanstat could offer dermatologists a mechanistically novel, sebum-directed oral option with year-long efficacy data at launch.